OGEDA SA

City:

Charleroi

Country:

Belgium

Published Applications:

Last publication date:

2021-04-01

Patent Grants:

Last grant date:

2023-08-22

Top Inventors for applications by OGEDA SA

These are the the leading inventors for applications assigned to OGEDA SA:

Graeme FRASER 8 Bousval, Belgium
Guillaume Dutheuil 7 Vedrin, Belgium
Hamid HOVEYDA 7 Bruxelles, Belgium
Hamid Hoveyda 7 Brussels, Belgium

Jerome BERNARD 1 BREGTIGNY, France
Ludivine Zoute 1 Vedrin, Belgium
Julien Parcq 1 Lille, France
Hamid R. Hoveyda 1 Brussels, Belgium

Didier Schils 1 Loupoigne, Belgium
Hamid R. Hoveyda 1 Bruxelles, Belgium

Recent patent applications by OGEDA SA

OGEDA SA based in Charleroi, BE has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2021-04-01 ✅ Patent 11,731,974 granted on 2023-08-22

US20210094959A1

Chemistry; metallurgy

N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists

#2 | 2018-08-23 ✅ Patent 10,214,533 granted on 2019-02-26

US20180237446A1

Chemistry; metallurgy

N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders

#3 | 2018-04-26 ✅ Patent 10,183,948 granted on 2019-01-22

US20180111943A1

Chemistry; metallurgy

N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists

#4 | 2018-03-08 ✅ Patent 9,969,745 granted on 2018-05-15

US20180065972A1

Chemistry; metallurgy

N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders

#5 | 2017-08-24 ✅ Patent 10,030,025 granted on 2018-07-24

US20170240551A9

Chemistry; metallurgy

Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists

#6 | 2017-04-06 ✅ Patent 9,987,274 granted on 2018-06-05

US20170095472A1

Human necessities

N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists

#7 | 2016-10-20 ✅ Patent 9,969,738 granted on 2018-05-15

US20160304521A1

Chemistry; metallurgy

-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders

#8 | 2016-10-20 ✅ Patent 9,770,435 granted on 2017-09-26

US20160303075A1

Human necessities

Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases

Also check out OGEDA SA's (Charleroi, Belgium) applicant profile with 7 patent applications submitted.

AssigneeID:

528957 ⎘